892579-09-8 Usage
Uses
Used in Organic Synthesis:
N-cyclopropyl-4-nitrobenzylamine is used as a building block in organic synthesis for the creation of various pharmaceuticals and biologically active compounds. Its unique structure allows for the development of new molecules with potential therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-cyclopropyl-4-nitrobenzylamine serves as a key component in the synthesis of drugs, contributing to the discovery and design of novel therapeutic agents.
Used as a Reagent in Chemical Reactions:
N-cyclopropyl-4-nitrobenzylamine is utilized as a reagent in various chemical reactions, facilitating the formation of desired products and aiding in the advancement of chemical processes.
Used in Catalytic Processes:
N-cyclopropyl-4-nitrobenzylamine also plays a role in catalytic processes, where it can act as a substrate to enhance the efficiency and selectivity of certain chemical transformations, contributing to the overall yield and purity of the end products.
Used in Chemical Research:
N-cyclopropyl-4-nitrobenzylamine is employed in chemical research to explore new reaction mechanisms, develop innovative synthetic routes, and understand the fundamental aspects of chemical reactivity and selectivity.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-cyclopropyl-4-nitrobenzylamine is used as a precursor in the synthesis of various drugs, helping to expand the range of available medications and improve treatment options for patients.
Used in Agrochemical Industry:
N-cyclopropyl-4-nitrobenzylamine may also find applications in the agrochemical industry, where it could be used in the development of new pesticides, herbicides, or other agricultural chemicals to enhance crop protection and yield.
Used in Material Science:
N-cyclopropyl-4-nitrobenzylamine's unique properties can be leveraged in material science for the development of new materials with specific characteristics, such as improved stability, reactivity, or selectivity in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 892579-09-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,2,5,7 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 892579-09:
(8*8)+(7*9)+(6*2)+(5*5)+(4*7)+(3*9)+(2*0)+(1*9)=228
228 % 10 = 8
So 892579-09-8 is a valid CAS Registry Number.
892579-09-8Relevant articles and documents
Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia
Wang, Yue,Zhi, Yanle,Jin, Qiaomei,Lu, Shuai,Lin, Guowu,Yuan, Haoliang,Yang, Taotao,Wang, Zhanwei,Yao, Chao,Ling, Jun,Guo, Hao,Li, Tonghui,Jin, Jianlin,Li, Baoquan,Zhang, Li,Chen, Yadong,Lu, Tao
, p. 1499 - 1518 (2018/03/05)
A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.
